Drug Profile
Leuprorelin depot - Xbrane
Alternative Names: LeuprosphereLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Primm srl
- Developer Xbrane
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Endometriosis; Precocious puberty; Prostate cancer; Uterine leiomyoma
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Breast cancer in Sweden (IV-injection)
- 24 Aug 2023 Discontinued - Preclinical for Endometriosis in Sweden (IV-injection)
- 24 Aug 2023 Discontinued - Preclinical for Precocious puberty in Sweden (IV-injection)